Navigation Links
Par Pharmaceutical Reports Third Quarter 2008 Results
Date:11/6/2008

Reports Adjusted EPS of $0.26

WOODCLIFF LAKE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced results for the third quarter ended Sept 27, 2008.

Third Quarter and Nine Month Results

For the third quarter ended September 27, 2008, Par reported total revenues of $149.0 million and net income of $1.7 million, or $0.05 per diluted share. This is compared with reported revenues of $212.7 million and net income of $1.3 million, or $0.04 per diluted share, for the same period in 2007. For the nine months ended September 27, 2008, Par reported total revenues of $416.8 million and a net loss of $15.8 million, or $0.47 per diluted share. This is compared with reported revenues of $614.5 million and net income of $45.6 million, or $1.30 per diluted share, for 2007.

Third quarter 2008 reported net income included the write-off of an intangible asset and certain inventories related to the trimming of its current generic product portfolio of $5.4 million, a charge relating to a government pricing contingency of $4.6 million, a $2.5 million impairment charge on an investment due to the downturn in the financial markets, a $1.25 million development milestone payment to MonoSol Rx, and a $2.2 million gain from the sale of non-core ANDAs. Adjusting for these one-time items, net income for the third quarter 2008 was $8.8 million, or $0.26 per diluted share. By comparison, net income in the third quarter 2007 included $16.2 million of costs related to business development activities in support of Strativa Pharmaceuticals. Adjusting for this one-time item, net income for the third quarter 2007 was $11.1 million, or $0.32 per diluted share.

Third Quarter Financial Review '/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
2. Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review
3. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
4. Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
6. Jazz Pharmaceuticals to Present at Investor Conferences
7. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
9. NeoStem Signs Definitive Agreement to Acquire Controlling Interest in a Leading Chinese Pharmaceutical Company
10. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
11. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... been recognized in the 2015 Aster Awards national competition for a marketing communications ... Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. , A ...
(Date:7/31/2015)... ... , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in ... announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a ... MaxLife will grant 100% of the money raised to BioViva to help bring pioneering ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held ... have to. , Instead of risking containment — or even destruction — of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital Tampa ... that was developed for targeted delivery of fluids to selected sites in the ... Florida Hospital Tampa with the device that provides direct, local delivery of chemotherapy ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National ... Thursday, September 17th at Ford Field in Detroit and the second match will occur ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
... for years about the health risks of using the Chicago ... Chicago study, canoeing, kayaking, rowing, boating and fishing on the ... performing these same activities on other local waters -- a ... for swimmers at Lake Michigan beaches. The study is ...
... is providing a new route to get to and remove ... natural hole behind the molars, above the jawbone and beneath ... surgery, published in the October the Laryngoscope , the ... faster recovery and fewer complications than traditional approaches. And, because ...
... Oct. 25 (HealthDay News) -- ,Marijuana causes disruptions in ... people with schizophrenia, according to a new study. ... neurons in the brains of rats given a drug ... of marijuana. The effects of the drug on ...
... A new potential leukemia therapy targets only cancer cells, ... treatments affect cancer cells and healthy cells, causing significant ... and depression. This research is being presented at ... Meeting and Exposition in Washington, D.C., Oct. 23 ...
... TUESDAY, Oct. 25 (HealthDay News) -- Scientists have identified mutations ... have a potentially fatal blood clot after undergoing heart stent ... the drug Plavix (clopidogrel), a widely used blood thinner, and ... Oct. 26 issue of the Journal of the American ...
... Sox and Yankee fans alike sitting inches away from the television, ... away It might have been that very moment in 2003 when ... it might have been that very moment in 2004, when Boston,s Pokey ... devastation of 2003 began to fade from the memories of so many ...
Cached Medicine News:Health News:Boaters' risk of illness on Chicago River similar to other waterways 2Health News:Boaters' risk of illness on Chicago River similar to other waterways 3Health News:New 'scarless' surgery takes out tumors through natural skull opening 2Health News:Genes Could Highlight Plavix Users at Clot Risk After Stent 2Health News:A World Series to remember? 2
(Date:7/31/2015)... -- RnRMarketResearch.com adds Syringes and Needles ... provides an overview of syringes and needles currently ... databases, secondary and primary research. Complete ... spread across 124 pages, talking about 13 companies ... figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
(Date:7/31/2015)... Fla. , July 31, 2015  Xcelience, ... today that it has made a structured cash ... -based company specializing in milling, micronization and powder ... will help grow Powdersize,s business while simultaneously adding ... to Xcelience,s portfolio of capabilities. ...
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... alvespimycin, the company,s second-generation Hsp90 inhibitor, in,patients with ... to disrupt the activity of multiple oncogenes,and cell ... a,key signaling pathway in breast cancer. The objective ...
... study conducted in MDS - Vidaza therapy confers highly significant 9.4 ... to conventional care regimens, - Two year overall survival rate of 50.8% ... ... Pharmion Corporation,(Nasdaq: PHRM ) today announced the submission of a ...
Cached Medicine Technology:Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 2Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 3Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 2Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 3Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 5Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 6Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 7
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro....
Lap pad used to protect pelvic regions...
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
Medicine Products: